Fourth-quarter device financing reached $4.2bn, up from the previous quarter’s $3.3bn. The initial public offering category made up the most, accounting for $1.3bn, or 32%, of the Q4 total, followed b
Health care-associated infections (HAIs) are largely attributed to the use of increasingly invasive devices and products; widespread use of respiratory support equipment; and the indiscriminate use of
Exhibit 1 Top Alliances In March 2014 (Potential Deal Value In $M) *Potential deal value is the sum of up-front fees plus pre-commercialization money. Strategic Transactions Exhibit 2 Top Mergers & Ac
IN VITRO DIAGNOSTICS Mergers & Acquisitions Roche Roche Molecular Diagnostics IQuum Inc. Roche paid $275mm up front for private molecular diagnostics company IQuum Inc. , which is also eligible